Anti-EGFR antibodies like cetuximab and panitumumab are effective in RAS wild-type tumors, while agents targeting HER2, such as trastuzumab, are undergoing evaluation in HER2-positive CRC. This evidence concerns the gene ERBB2 and colorectal carcinoma.